Lower interest rates aided the biotech bounceback, as many companies in the sector rely on a big dose of debt. Their shares also rose as the number of patent cliffs for blockbuster drugs increased, ...
Technical shifts are forcing a fresh look.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results